Finerenone in Persons with Chronic Kidney Disease without Diabetes.
Summary
In FIND-CKD, a randomized, double-blind trial in 1,584 adults with CKD but without diabetes, finerenone slowed the decline in eGFR versus placebo over 32 months. This extends mineralocorticoid receptor antagonist benefits beyond diabetic CKD.
Key Findings
- Randomized 1,584 adults with CKD and no diabetes to finerenone vs placebo.
- Finerenone slowed the decline in eGFR over 32 months compared with placebo.
- Baseline mean eGFR was 46.8 mL/min/1.73 m2; effects observed across the randomized population.
Clinical Implications
Finerenone may be considered to slow kidney function decline in adults with CKD without diabetes, pending regulatory and guideline alignment; monitoring and patient selection strategies should be defined.
Why It Matters
First high-quality RCT to show renal benefit of finerenone in CKD without diabetes, potentially expanding indications and informing guideline updates.
Limitations
- Abstract reports eGFR slope benefit; detailed hard kidney endpoints (e.g., ESKD) are not specified in the provided text
- Generalizability across CKD etiologies requires further subgroup detail
Future Directions
Define optimal patient selection, safety monitoring, and impact on hard renal outcomes and cardiovascular endpoints in non-diabetic CKD; cost-effectiveness and implementation studies are warranted.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized, double-blind, placebo-controlled clinical trial
- Study Design
- OTHER